BAX and ovarian cancer: There were no differences in the genotype distribution between the patients with ovarian cancer and the healthy women (for BAX GG: 75.51% vs. 73.00%, OR = 1.14; GA: 23.47% vs. 25.00, OR = 1.09; AA: 1.02 vs. 2.00, OR = 1.10; p = 0.401; for c-MYC AA: 33.67% vs. 38.00%, OR = 0.82; AG: 42.86% vs. 42.00%, OR = 0.96; GG: 23.47% vs. 20.00%, OR = 0.81; p = 0.331).